Screening for hydroxychloroquine toxicity by Texas ophthalmologists

Preston H. Blomquist, Ravi K. Chundru

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective. To determine current practice patterns for screening for hydroxychloroquine (HCQ) toxicity by Texas ophthalmologists. Methods. A survey was sent to all comprehensive ophthalmologists and retina specialists in the state of Texas. Questions included need for baseline examinations, frequency of followup, tests used to monitor for toxicity, and influences on monitoring regimen. Results. Two hundred ninety of 577 surveys were returned correctly completed (response rate = 50.3%). Two hundred fifty-seven respondents (88.6%) felt a baseline examination was necessary prior to beginning HCQ therapy, and 223 (76.9%) followed patients every 6 months during HCQ therapy. Visual acuity, slit lamp examination, and dilated fundus examination were performed on almost all patients, and about three-quarters of respondents also checked visual fields and color vision. While 183 ophthalmologists (63.1%) used the Ishihara pseudoisochromatic plates to check color vision, there was no consensus on the preferred visual field test. One hundred twenty-two respondents (42.1%) stated they had diagnosed a patient with HCQ ocular toxicity. Conclusion. Most ophthalmologists in Texas continue to perform baseline examinations and follow HCQ patients semiannually for the development of ocular toxicity despite recent recommendations questioning the need for such close followup. The majority check visual acuity, perform slit lamp and dilated fundus examinations, and test color vision and visual fields, although there is no consensus on the preferred method to test visual fields.

Original languageEnglish (US)
Pages (from-to)1665-1670
Number of pages6
JournalJournal of Rheumatology
Volume29
Issue number8
StatePublished - 2002

Fingerprint

Hydroxychloroquine
Color Vision
Visual Field Tests
Visual Fields
Visual Acuity
Consensus
Retina
Ophthalmologists
Surveys and Questionnaires
Therapeutics

Keywords

  • Adverse effects
  • Antirheumatic agents
  • Chemically induced retinal diseases
  • Drug monitoring
  • Hydroxychloroquine

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Screening for hydroxychloroquine toxicity by Texas ophthalmologists. / Blomquist, Preston H.; Chundru, Ravi K.

In: Journal of Rheumatology, Vol. 29, No. 8, 2002, p. 1665-1670.

Research output: Contribution to journalArticle

@article{c57fe3d638254734a7583a68c3f64508,
title = "Screening for hydroxychloroquine toxicity by Texas ophthalmologists",
abstract = "Objective. To determine current practice patterns for screening for hydroxychloroquine (HCQ) toxicity by Texas ophthalmologists. Methods. A survey was sent to all comprehensive ophthalmologists and retina specialists in the state of Texas. Questions included need for baseline examinations, frequency of followup, tests used to monitor for toxicity, and influences on monitoring regimen. Results. Two hundred ninety of 577 surveys were returned correctly completed (response rate = 50.3{\%}). Two hundred fifty-seven respondents (88.6{\%}) felt a baseline examination was necessary prior to beginning HCQ therapy, and 223 (76.9{\%}) followed patients every 6 months during HCQ therapy. Visual acuity, slit lamp examination, and dilated fundus examination were performed on almost all patients, and about three-quarters of respondents also checked visual fields and color vision. While 183 ophthalmologists (63.1{\%}) used the Ishihara pseudoisochromatic plates to check color vision, there was no consensus on the preferred visual field test. One hundred twenty-two respondents (42.1{\%}) stated they had diagnosed a patient with HCQ ocular toxicity. Conclusion. Most ophthalmologists in Texas continue to perform baseline examinations and follow HCQ patients semiannually for the development of ocular toxicity despite recent recommendations questioning the need for such close followup. The majority check visual acuity, perform slit lamp and dilated fundus examinations, and test color vision and visual fields, although there is no consensus on the preferred method to test visual fields.",
keywords = "Adverse effects, Antirheumatic agents, Chemically induced retinal diseases, Drug monitoring, Hydroxychloroquine",
author = "Blomquist, {Preston H.} and Chundru, {Ravi K.}",
year = "2002",
language = "English (US)",
volume = "29",
pages = "1665--1670",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "8",

}

TY - JOUR

T1 - Screening for hydroxychloroquine toxicity by Texas ophthalmologists

AU - Blomquist, Preston H.

AU - Chundru, Ravi K.

PY - 2002

Y1 - 2002

N2 - Objective. To determine current practice patterns for screening for hydroxychloroquine (HCQ) toxicity by Texas ophthalmologists. Methods. A survey was sent to all comprehensive ophthalmologists and retina specialists in the state of Texas. Questions included need for baseline examinations, frequency of followup, tests used to monitor for toxicity, and influences on monitoring regimen. Results. Two hundred ninety of 577 surveys were returned correctly completed (response rate = 50.3%). Two hundred fifty-seven respondents (88.6%) felt a baseline examination was necessary prior to beginning HCQ therapy, and 223 (76.9%) followed patients every 6 months during HCQ therapy. Visual acuity, slit lamp examination, and dilated fundus examination were performed on almost all patients, and about three-quarters of respondents also checked visual fields and color vision. While 183 ophthalmologists (63.1%) used the Ishihara pseudoisochromatic plates to check color vision, there was no consensus on the preferred visual field test. One hundred twenty-two respondents (42.1%) stated they had diagnosed a patient with HCQ ocular toxicity. Conclusion. Most ophthalmologists in Texas continue to perform baseline examinations and follow HCQ patients semiannually for the development of ocular toxicity despite recent recommendations questioning the need for such close followup. The majority check visual acuity, perform slit lamp and dilated fundus examinations, and test color vision and visual fields, although there is no consensus on the preferred method to test visual fields.

AB - Objective. To determine current practice patterns for screening for hydroxychloroquine (HCQ) toxicity by Texas ophthalmologists. Methods. A survey was sent to all comprehensive ophthalmologists and retina specialists in the state of Texas. Questions included need for baseline examinations, frequency of followup, tests used to monitor for toxicity, and influences on monitoring regimen. Results. Two hundred ninety of 577 surveys were returned correctly completed (response rate = 50.3%). Two hundred fifty-seven respondents (88.6%) felt a baseline examination was necessary prior to beginning HCQ therapy, and 223 (76.9%) followed patients every 6 months during HCQ therapy. Visual acuity, slit lamp examination, and dilated fundus examination were performed on almost all patients, and about three-quarters of respondents also checked visual fields and color vision. While 183 ophthalmologists (63.1%) used the Ishihara pseudoisochromatic plates to check color vision, there was no consensus on the preferred visual field test. One hundred twenty-two respondents (42.1%) stated they had diagnosed a patient with HCQ ocular toxicity. Conclusion. Most ophthalmologists in Texas continue to perform baseline examinations and follow HCQ patients semiannually for the development of ocular toxicity despite recent recommendations questioning the need for such close followup. The majority check visual acuity, perform slit lamp and dilated fundus examinations, and test color vision and visual fields, although there is no consensus on the preferred method to test visual fields.

KW - Adverse effects

KW - Antirheumatic agents

KW - Chemically induced retinal diseases

KW - Drug monitoring

KW - Hydroxychloroquine

UR - http://www.scopus.com/inward/record.url?scp=0036021140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036021140&partnerID=8YFLogxK

M3 - Article

C2 - 12180726

AN - SCOPUS:0036021140

VL - 29

SP - 1665

EP - 1670

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -